Gilead Sciences Inc. has divulged nucleoside phospholipid compounds reported to be useful for the treatment of viral infections.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, and inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.

Chengdu Kanghong Pharmaceutical Co. Ltd. has synthesized indazolinone compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of cardiovascular disorders, cerebral infarction, dementia, diabetes, hyperlipidemia, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), obesity and stroke.

Apogee Pharmaceuticals Inc. has disclosed monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neurodegeneration, neuropathy, ischemia, and metabolic, eye, lung, inflammatory and renal disorders, among others.

Jiangsu Vcare Pharmatech Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) targeting moiety via a linker reported to be useful for the treatment of cancer.

Nanjing Mingde New Drug Research Co. Ltd. has divulged pyrimidinone derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists reported to be useful for the treatment of cough.

Merck Sharp & Dohme LLC has identified plasma kallikrein (KLKB1) Inhibitors reported to be useful for the treatment of diabetic retinopathy, retinal vein occlusion, hereditary angioedema, diabetes, pancreatitis, intracerebral hemorrhage, nephropathy and inflammatory disorders.

Arase Therapeutics Inc. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Nanjing Huanbo Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to a β-adrenergic receptor kinase 1 (BARK1; GRK2) targeting moiety via a linker acting as GRK2 degradation inducers.

Hitgen Ltd. has described protein cereblon (CRBN) inhibitors reported to be useful for the treatment of cancer.